Rezultati pretrage - Peter S. Hammerman

Detaljiziraj rezultate
  1. 1
    Genomic Landscape of Human Papillomavirus–Associated Cancers

    Genomic Landscape of Human Papillomavirus–Associated Cancers od Maria Rusan, Yvonne Y. Li, Peter S. Hammerman

    Izdano 2015
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  2. 2
    The Pim kinases control rapamycin-resistant T cell survival and activation

    The Pim kinases control rapamycin-resistant T cell survival and activation od Casey Fox, Peter S. Hammerman, Craig B. Thompson

    Izdano 2005
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  3. 3
    Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

    Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer od Peter S. Hammerman, Pasi A. Jänne, Bruce E. Johnson

    Izdano 2009
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  4. 4
    Therapeutic Insights from Genomic Studies of Head and Neck Squamous Cell Carcinomas

    Therapeutic Insights from Genomic Studies of Head and Neck Squamous Cell Carcinomas od Peter S. Hammerman, D. Neil Hayes, Jennifer R. Grandis

    Izdano 2015
    Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  5. 5
    Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival

    Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival od Peter S. Hammerman, Casey Fox, Morris J. Birnbaum, Craig B. Thompson

    Izdano 2005
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  6. 6
    Non-small-cell lung cancers: a heterogeneous set of diseases

    Non-small-cell lung cancers: a heterogeneous set of diseases od Chen Zhao, Christine M. Fillmore, Peter S. Hammerman, Carla F. Kim, Kwok‐Kin Wong

    Izdano 2014
    Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  7. 7
    Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics

    Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics od David R. Gandara, Peter S. Hammerman, Martin L. Sos, Primo N. Lara, Fred R. Hirsch

    Izdano 2015
    Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  8. 8
    The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor

    The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor od Casey Fox, Peter S. Hammerman, Ryan M. Cinalli, Stephen R. Master, Lewis A. Chodosh, Craig B. Thompson

    Izdano 2003
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  9. 9
    Akt-Directed Glucose Metabolism Can Prevent Bax Conformation Change and Promote Growth Factor-Independent Survival

    Akt-Directed Glucose Metabolism Can Prevent Bax Conformation Change and Promote Growth Factor-Independent Survival od Jeffrey C. Rathmell, Casey Fox, David R. Plas, Peter S. Hammerman, Ryan M. Cinalli, Craig B. Thompson

    Izdano 2003
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  10. 10
    Lymphocyte Transformation by Pim-2 Is Dependent on Nuclear Factor-κB Activation

    Lymphocyte Transformation by Pim-2 Is Dependent on Nuclear Factor-κB Activation od Peter S. Hammerman, Casey Fox, Ryan M. Cinalli, Anne Xu, John D. Wagner, Tullia Lindsten, Craig B. Thompson

    Izdano 2004
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  11. 11
    Genomic Analysis of Metastatic Cutaneous Squamous Cell Carcinoma

    Genomic Analysis of Metastatic Cutaneous Squamous Cell Carcinoma od Yvonne Y. Li, Glenn J. Hanna, Alvaro C. Laga, Robert I. Haddad, Jochen H. Lorch, Peter S. Hammerman

    Izdano 2015
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  12. 12
    Characterization of DDR2 Inhibitors for the Treatment of <i>DDR2</i> Mutated Nonsmall Cell Lung Cancer

    Characterization of DDR2 Inhibitors for the Treatment of <i>DDR2</i> Mutated Nonsmall Cell Lung Cancer od Hideki Terai, Li Tan, Ellen M. Beauchamp, John M. Hatcher, Qingsong Liu, Matthew Meyerson, Nathanael S. Gray, Peter S. Hammerman

    Izdano 2015
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  13. 13
    Multiple signaling pathways promote B lymphocyte stimulator–dependent B-cell growth and survival

    Multiple signaling pathways promote B lymphocyte stimulator–dependent B-cell growth and survival od Robert T. Woodland, Casey Fox, Madelyn R. Schmidt, Peter S. Hammerman, Joseph T. Opferman, Stanley J. Korsmeyer, David M. Hilbert, Craig B. Thompson

    Izdano 2007
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  14. 14
    Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma

    Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma od Jeremy S. Abramson, Matthew D. Hellmann, Jeffrey A. Barnes, Peter S. Hammerman, Christiana E. Toomey, Tak Takvorian, Alona Muzikansky, Ephraim P. Hochberg

    Izdano 2010
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  15. 15
    Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells

    Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells od Jun Wang, Oliver R. Mikse, Rachel G. Liao, Yi Li, Li Tan, Pasi A. Jänne, Nathanael S. Gray, K-k Wong, Peter S. Hammerman

    Izdano 2014
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  16. 16
    Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand

    Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand od Daniel E. Bauer, Marian H. Harris, David R. Plas, Julian J. Lum, Peter S. Hammerman, Jeffrey C. Rathmell, James L. Riley, Craig B. Thompson

    Izdano 2004
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  17. 17
    Treatment-Related Toxicities in a Phase II Trial of Dasatinib in Patients with Squamous Cell Carcinoma of the Lung

    Treatment-Related Toxicities in a Phase II Trial of Dasatinib in Patients with Squamous Cell Carcinoma of the Lung od Andrew M. Brunner, Daniel B. Costa, Rebecca S. Heist, Elizabeth Garcia, Neal I. Lindeman, Lynette M. Sholl, Geoffrey R. Oxnard, Bruce E. Johnson, Peter S. Hammerman

    Izdano 2013
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  18. 18
    Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by<i>DDR2</i>Gatekeeper Mutation and<i>NF1</i>Loss

    Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by<i>DDR2</i>Gatekeeper Mutation and<i>NF1</i>Loss od Ellen M. Beauchamp, Brittany A. Woods, Austin Dulak, Li Tan, Chunxiao Xu, Nathanael S. Gray, Adam J. Bass, Kwok‐Kin Wong, Matthew Meyerson, Peter S. Hammerman

    Izdano 2013
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  19. 19
    Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer

    Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer od Amit Dutt, Alex H. Ramos, Peter S. Hammerman, Craig H. Mermel, Jeonghee Cho, Tanaz Sharifnia, Ajit Chande, Kumiko Tanaka, Nicolas Stransky, Heidi Greulich, Nathanael S. Gray, Matthew Meyerson

    Izdano 2011
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  20. 20
    Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application

    Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application od Young Kwang Chae, Keerthi Ranganath, Peter S. Hammerman, Christos Vaklavas, Nisha Mohindra, Aparna Kalyan, Maria Matsangou, Ricardo Costa, Benedito A. Carneiro, Victoria Villaflor, Massimo Cristofanilli, Francis J. Giles

    Izdano 2016
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:

Alati za pretragu: